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Bobak David Kechavarzi 
DEVELOPING BOTTOM-UP, INTEGRATED OMICS METHODOLOGIES FOR BIG 
DATA BIOMARKER DISCOVERY 
The availability of highly-distributed computing compliments the proliferation of 
next generation sequencing (NGS) and genome-wide association studies (GWAS) 
datasets. These data sets are often complex, poorly annotated or require complex domain 
knowledge to sensibly manage. These novel datasets provide a rare, multi-dimensional 
omics (proteomics, transcriptomics, and genomics) view of a single sample or patient. 
Previously, biologists assumed a strict adherence to the central dogma: 
replication, transcription and translation. Recent studies in genomics and proteomics 
emphasize that this is not the case. We must employ big-data methodologies to not only 
understand the biogenesis of these molecules, but also their disruption in disease states. 
The Cancer Genome Atlas (TCGA) provides high-dimensional patient data and illustrates 
the trends that occur in expression profiles and their alteration in many complex disease 
states. 
I will ultimately create a bottom-up multi-omics approach to observe biological 
systems using big data techniques. I hypothesize that big data and systems biology 
approaches can be applied to public datasets to identify important subsets of genes in 
cancer phenotypes. By exploring these signatures, we can better understand the role of 
amplification and transcript alterations in cancer. 
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 The goal of this dissertation is to detail the transcriptional landscape of cancers 
and the alterations that occur from healthy to diseased states.  This necessitates a 
multifaceted approach to gain a fundamental understanding of transcriptional regulation, 
how transcriptional abundancies and copy number alterations impact protein production, 
and finally, how transcriptional consistently can uniquely identify diseases. 
1.1.1 Dissecting the expression landscape of RNA-binding proteins in human cancers  
The expression signature of four transcriptional and posttranscriptional regulators 
(RNA binding proteins, micro-RNA, transcription factors, and long, non-coding RNA) 
were analyzed in 16 healthy human tissues.  In particular, I focus on RNA binding 
proteins due to their importance in complex diseases and a poor understanding of their 
expression in human tissues.  Based on these signatures I inferred their regulatory 
importance based on expression levels in key developmental tissues.  Furthermore, I 
leveraged the publicly available data in The Cancer Genome Atlas to determine how their 
expression was altered from the healthy to disease state across nine human cancers.  
Examining these changes highlighted a subset of these regulators that are disrupted in 
cancer, suggesting potential biomarkers.  Using additional interaction data, I estimated 
what downstream components might be impacted by these genes.  This portion of 
research provides the groundwork in processing expression and metadata from TCGA, as 





1.1.2 Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive  
genes in breast cancer samples from TCGA 
 Now that I have profiled and identified aggressive patterns of enhanced 
expression, I have to understand how that impacts the actual production of protein within 
the cell.  Often mRNA or transcript abundances are used as surrogates of the products 
produced by genes; however, new consortia offer proteomics data from processed TCGA 
samples.  In this effort, copy number variation, mRNA foldchanges, and protein 
foldchanges for breast adenocarcinoma samples from TCGA were leveraged to globally 
determine dosage sensitivity.  A subset of genes (broadly dosage sensitive genes, 
BDSGs) were identified by leveraging their correlation of copy number, mRNA, and 
protein features among samples.  These genes can emphasize an important subclass of 
genes that could be useful for better understanding of cancer.  By observing their 
behavior in single-cell shRNA models, one can attempt to estimate if these genes can 
contribute in the form of cancer suppression, cancer enhancement, or more generally as 
housekeeping genes. 
1.1.3 Deep Learning and transcriptional signatures for identifying key differentiating  
genes in cancer histologies 
 My previous exploration emphasized a unique subset of genes that demonstrated a 
strong correlation across the three genomic features in breast cancer.  Next, the analysis 
can be expanded to incorporate more recently available data and compare signatures 
between breast adenocarcinoma and ovarian carcinoma.  Expanding the data allows us to 
observe any unique or overlapping genes between the two histologies.  It also provides 
the opportunity to compare overall transcriptional differences between the two cancer 
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types.  Deep neural networks were employed to train a model to differentiate samples 
between ovarian and breast cancer types.  Utilizing deep learning afforded us the ability 
to use multimodal data to determine both the importance of the different genomic data 
types and the individual contributions on each of the genes in the classification task.  
Deep learning implementations allowed us to conduct these observations without having 
to perform feature extraction or prioritization prior to training (Figure 1). Shapley 
additive explanations allowed us to determine a gene’s contribution in the effective 
sample classification.  These values can provide a “weighting” to the previously 
identified BDSGs to determine if they do, in fact, differentiate sample types.  Doing so 
helped illustrate if these genes are unique between histologies and identify which disease 
state a sample is in. 
 
Figure 1: Representation of different automated learning methodologies.  An 
illustrative example of the differences between machine learning and deep learning.  In 
this case, it is not required to predetermine or prioritize features manually or through 
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personal intervention.  Deep learning allows the feature extraction and classification steps 
to occur simultaneously. 
1.2 Significance 
Recently, DNA sequencing technologies have advanced tremendously. They can 
provide insights into structural variations as well as the abundance of transcripts within 
the samples, which benefit many biomedical studies.  The proliferation and availability of 
these datasets also provide the opportunity to do largescale, cross-domain analyses. This 
is thwarted by finding datasets that have complete coverage over proteomic, genomic, 
epigenetic, and transcriptomic features.  The Cancer Genome Atlas (TCGA) collects data 
for patients over 30 types of cancer and a wide array of -omics data.   In 2015 
approximately 40,000 women died of breast cancer.   Understanding this disease space 
impacts a large population of suffering individuals and is aided by large, 
multidimensional datasets available for many patients.   
It is essential to gain a firm grasp on the expression of genes in various tissues, 
how their signatures may change in each site, and the alteration that may occur from a 
healthy to a disease state.  Previously, these systems-level observations were made with 
specific gene sets or pathways in mind. I leveraged big-data approaches to integrate large 
scale genomics, proteomics, and clinical data to observe overall trends throughout the 
genome.  
• First, I observed how mRNA abundance levels for different classes of post-
transcriptional and transcriptional regulators change from tissue to tissue, 
emphasizing their regulatory capacity in those sites.   
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• I extended the understanding by detailing their abundance changes in cancer; 
emphasizing potential dysregulators or onco-genes.   
• I integrated proteomics and copy number variation data to understand how the 
genes adhere to the central dogma and if the alterations impact the production of 
proteins.  
• Finally, I generated comprehensive, integrated views across multiple histologies 
to determine perturbations that may emphasize putative biomarkers.  
Ultimately, I generated a big data omics system to better perform bottom-up 
hypothesis testing. It will look at the sample data in their entirety to identify meaningful 
signatures that can elucidate new biomarkers that would have been otherwise missed due 
to a bias. 
1.3 Contribution 
I engineered a computational framework to perform big-data queries across 
varied, complex biological datasets.  The investigation also provided a technical solution 
in data structures and workflow methodologies for large-scale genomics.  A signature 
catalog of gene expression over thousands of samples, tissues, and cancer types was 
produced for large-scale analytics.   The integration of protein fold changes, mRNA 
abundances, and copy number variation across a variety of cancer types and patients is an 
unprecedented opportunity to conduct truly systems-level observations.  Leveraging deep 
learning methodologies further emphasized the disruption occurring in the tissues and 
how seemingly unrelated genes are acting to differentiate samples.  Furthermore, a data 
dashboard of the results was created and distributed using container-based virtualization 
to preserve the results.  This effort itself demonstrates the strength of non-traditional data 
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storage and processing, such as in-memory databases and deep neural networks in 
extending systems biology analyses.  
1.4 Challenges 
 One of the most pressing challenges in an effort such as this was the missing or 
incomplete data.  Aim 1 began early in the development life of the TCGA project and 
sample coverage across the multiple histologies was only just beginning.  Some data had 
to be discarded because of incompleteness or low sample diversity.  In Aims 2 and 3, for 
example, samples had to be excluded because of missing proteomics data.  Careful 
consideration had to be given early on to data design and engineering.  Schema needed to 
be resilient enough to add or remove data, but not become too unwieldy for the later, 
intensive computational tasks.  For machine learning tasks, considerable work was 
necessary to define negative controls.  Analyzing such large volumes of data often 
introduce correlations that can add false signals for sample differentiation.  For example, 
for Aim 3 several models were able to differentiate samples because the model identified 
age-differentiating genes that illustrated an age bias between ovarian and breast cancer 
samples.     
Careful unit testing and best software practices for parallelized systems were used 
to quickly perform the computations identifying correlational patterns across three 
genomic data types and thousands of samples in Aim 2.  In general, the data volume and 
computational complexity derived most the challenges in these analyses, and even 
directed the research to leverage deep-learning methodologies.  Most standard machine 
learning or clustering approaches do not perform well with several hundred-thousand 
features.  To do so would have required feature reduction techniques and would have 
 
7 
defeated the purpose of performing these bottom-up analyses. Even still, training the deep 
models required careful consideration in the architecture because of the large volume of 
features, even GPUs can only accommodate a certain volume of data. 
These challenges helped to emphasize how technological consideration and data 
engineering have become integral in scientific study design.  Addressing these aspects 
encouraged developing skills and solutions in high performance databases and distributed 
systems, as well as the aforementioned deep learning frameworks such as TensorFlow 
and Keras. 
1.5 Organization of the study 
Public transcriptomic datasets are utilized to describe the activity of various 
classes of genes and determine if there is an impact or correlation to a disease state. 
Figure 2 illustrates the aims and their relationships.  Figures 3 and 12 illustrate the 
workflows for the RNA binding protein expression exploration and BDSG identification, 
respectively.  In general, I leverage an aggregated normal control to determine expression 
changes from healthy to disease states.  Afterwards additional analytical steps are 




Figure 2:  Aims of the study and their relationships.  (A) Aim 1 begins the study with 
the most comprehensive assessment across multiple tissues, but only regarding one 
genomic data type.  Aim 2 expands the investigation of breast adenocarcinoma by 
including two additional genomic datatypes.  Aim 3 then looks across multiple cancer 
types using the same methodology as Aim 2 to derive a feature set for deep neural 
network models for sample identification. (B) Methodological relationship of the aims. 
The first aim of the dissertation provides an initial overview of the expression of 
cornerstone transcriptional regulators in a variety of healthy human tissues.  The study 
expands to include the changes in their expression from the healthy to the cancerous 
state.  In particular, RBPs are identified which were substantially enhanced and had 
impacts on patient survivability.  The second goal allowed us to expand the 
understanding of past mRNA changes.  With the inclusion of copy number and protein 
data, genes are identified whose genomic alterations are reflected in their protein 
production.  Additionally, these genes behavior are described via cell line models and 
shRNA experiments.  Finally, the differences in these gene sets are compared across 
 
9 







2. Dissecting the expression landscape of RNA-binding proteins in human cancers 
 
2.1 Background 
RNA-binding proteins (RBPs) have been identified as key regulatory components 
interacting with the RNA within a cell. Their function is largely dependent on their 
expression and localization within a cell. They may be involved in processes ranging 
from alternative splicing to RNA degradation. Combining together, RBPs form dynamic 
ribonucleoprotein (RNP) complexes, often in a highly combinatorial fashion that can 
affect all aspects of the life of RNA [1–3]. Due to their central role in controlling gene 
expression at the post-transcriptional level, alterations in expression or mutations in either 
RBPs or their binding sites in target transcripts have been reported to be the cause of 
several human diseases such as muscular atrophies, neurological disorders and cancer 
(reviewed in [4–7]). These studies suggest there is precise regulation of expression levels 
of RBPs in a cell.  
A recent system-wide study of the dynamic expression properties of yeast RBPs 
showed that RBPs with a high number of RNA targets are likely to be tightly regulated. 
Significant changes in their expression levels can bring about large-scale changes in the 
post-transcriptional regulatory networks controlled by them [8]. RBPs have also been 
shown to autoregulate their expression levels. Fluctuations in the expression of 
autoregulatory RBPs are significantly decreased [9]. These results show that a low degree 
of expression noise for RBPs is a characteristic feature of their normal state. 
Cancer is a complex genetic disease and many of its regulatory factors have been 
identified as being irregularly expressed. In particular, changes in the normal expression 
 
11 
of RBPs have been shown to alter their function leading to a cancer phenotype [10]. 
Enhanced eIF4E and HuR expression levels have been implicated in initiating translation 
of mRNAs encoding mostly for pro-oncogenic proteins and other cancer-promoting 
processes. For instance, Sam68 regulates the alternative splicing of cancer-related 
mRNAs [10]. Yet another example is the cell-specific alternative splicing of FAS (Fas 
cell surface death receptor, a member of the TNF receptor superfamily) mRNA. This has 
been linked to cancer predisposition depending on whether the pro- or anti-apoptotic 
protein form is produced as a result of the interplay between various RBPs on the FAS 
transcript [11–14]. In some cases, disruption of the functionality of RBPs, although 
without directly acting on oncogenic genes, has been shown to affect alternative splicing 
regulation or the regulation of alternative cleavage mechanisms on transcripts, which can 
lead to the development of cancer [15,16]. 
In a recent study, Castello and co-workers [17] utilized cross-linking and 
immunoprecipitation (CLIP) and photoactivatable-ribonucleoside-enhanced CLIP (PAR-
CLIP) to isolate and validate, via proteomics, a set of approximately 850 high-confidence 
RBPs in humans. These approaches can be used to catalogue and study RBPs and their 
post-transcriptional networks in healthy and diseased states. By knowing the low degree 
of expression variation that is tolerated by RBPs in a healthy state and identifying them in 
mammalian systems, we can begin to investigate their dysregulation profiles in various 
disease conditions.  
In this study, I analyzed the expression patterns of RBPs in a set of 16 healthy 
human tissues and compared their fold change in expression levels in nine human cancers 
using the high-resolution expression profiles based on RNA sequencing (RNA-seq) 
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available from the Human BodyMap (HBM) [18]and the Cancer Genome Atlas (TCGA) 
[19] (see Figure 3, which outlines the different steps, and Materials and methods). The 
network properties of a set of 31 RBPs were compared, which were found to be strongly 
upregulated (SUR) for most of the cancers studied. The network properties may help to 
determine the cause of the altered expression for the RBPs. Finally, a subset of RBPs was 
identified based on their expression profiles and network metrics and their contribution to 
the survival of patients with breast cancer was investigated. 
 
Figure 3: Flow chart showing the different steps in the analysis of expression levels 
of RNA-binding proteins for human cancers. The flow chart shows the acquisition and 
preparation of data (red), determination of patterns of dysregulation (green), network and 
interaction analysis (light blue), and survival analysis (dark blue). 
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2.2 Materials and methods 
2.2.1 Data for healthy expression of RNA-binding proteins in 16 human tissues 
 The general workflow is illustrated in Figure 3. RNA-seq data for 16 different 
human tissues from ArrayExpress [20] (Accession no. E-MTAB-513), which is part of 
the Human BodyMap (HBM) 2.0 project [18,21], was obtained for expression profiling. 
This data represents the healthy RNA transcript levels of male and female individuals 
aged 19 to 86, for 16 tissues: adipose, adrenal, brain, breast, colon, heart, kidney, liver, 
lung, lymph node, ovary, prostate, skeletal muscle, testes, thyroid and white blood cells. 
Expression data from the HBM project was quantified per transcript using the current 
annotations of the human genome from the Ensembl. This is available as reads per 
kilobase per millions of reads (RPKM) for each sample and hence can be compared 
across and within tissues. Therefore, each of the 16 tissues has a single RPKM value for 
the expression level of each transcript. A total of 850 genes experimentally characterized 
as RBPs in the human genome were obtained from a previous publication [17] and 4,647 
transcripts associated with these RBPs were identified within the HBM set. The 
remaining set of 102,462 transcripts were classified as non-RBPs in this study. To 
examine the other regulatory factors in humans I obtained a set of 9,440 long non-coding 
RNAs (lncRNAs) from a Gencode study [18,22], 529 microRNAs (miRNAs) from 
miRBase [23] and 1,231 transcription factors (TFs) from the DBD database [24]. For 
each of the 16 tissues distribution of the RPKM values for transcripts associated with 
RBPs and non-RBPs were compared, as well as the distribution of expression levels of 
transcripts associated with RBPs with other regulatory factors to study their relative 
effect on regulatory control at the tissue level. 
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2.2.2 Data for cancer expression of RNA-binding proteins for nine cancers in humans 
 The cancer expression data was downloaded from TCGA [19]. TCGA provides 
multi-level data (clinical, genome sequencing, microarray, RNA sequencing and so on) 
procured from a number of institutions, from a variety of patients, for over 25 cancers. In 
this study, RNAseq V2.0 data for 2,876 patients were collected spanning nine cancers 
analogous to eight of the tissues in the HBM dataset: breast (850 patients), brain (175 
patients), colon (193 patients), kidney (481 patients), liver (35 patients), two for lung 
(356 and 260 patients), prostate (141 patients), and thyroid (385 patients). For each 
cancer I collected the expression levels for each gene for all patients and determined a 
median representative level and MAD. This defines the genes’ RNA expression levels 
and variability in the relevant cancer state. Likewise, cancer expression and variation 
were determined for the group of non-RBP genes from HBM as a complementary group 
for later network, interaction, and expression analyses. Hierarchical clustering of RBP 
expression for these nine cancers was performed in R, to determine if similar cancers and 
tissues group together (Figure 6). Clustering results verified that the collected and 
amalgamated data are an accurate representation of their anatomical origin and can be 
utilized to draw further conclusions. 
2.2.3 Profiling for dysregulation of RNA-binding proteins and identification of strongly 
upregulated RNA-binding proteins across human cancers 
 For each gene identified as an RBP, I calculated a median expression level of its 
transcript products in the HBM data when there were multiple protein coding transcripts. 
To determine the extent of dysregulation in RBPs across cancers, for each cancer the log-
ratio of the median expression in the cancer state over its expression in the associated 
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healthy state was calculated. This allowed us to determine for the nine cancers if a 
particular gene annotated as an RBP is upregulated, downregulated or does not change in 
expression level in cancer states. Based on this analysis, if an RBP has a log-ratio of 
expression level greater than 9 across six or more of the studied cancers, it was classified 
as being SUR. Otherwise, it was categorized as non-SUR. I focused mainly on defining 
characteristics unique to these SUR RBPs that differentiate them from other RBPs and 
non-RBPs. SUR genes as defined here were also observed in non-RBPs and a 
hypergeometric test was performed to examine potential differences in the proportionality 
of SUR RBPs and non-SUR RBPs between the two functional classes. The genes 
associated with RBPs and non-RBPs were also classified by their level of expression 
variability in a cancer, measured as the MAD value of the fold change in expression for 
the profiled patients for the cancer. If a gene’s variability within a cancer was above the 
75th percentile, it was considered highly variable, below the 25th percentile it was 
considered least variable and the remainder were considered moderately variable. 
2.2.4 Network and interaction properties of dysregulated RNA-binding protein in human 
cancers 
 The most recent BioGRID [25] protein–protein interaction (PPI) information 
(version 3.2.97) was downloaded and used to construct an undirected network of 
interactions documented in humans. These interactions were used to determine if there 
were any differences in network properties between the two classifications of 
dysregulated RBPs, that is, SUR and non-SUR RBPs. This allowed the determination of 
the potential importance of the classifications for these RBPs. For example, if an SUR 
RBP forms a hub, it could cause patterns of dysregulation in other, associated interactors. 
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Network centrality measures were compared such as degree, closeness and betweenness 
as well as clustering coefficients and shortest paths between nodes, for different RBP 
classes utilizing the R package igraph [26]. For shortest paths, I calculated the mean 
shortest paths for a SUR RBP to other SUR RBPs and SUR RBPs to non-SUR RBPs. 
The overall average path length was obtained between each RBP/non-RBP and SUR 
RBP/non-SUR RBP combination. 
 Manually curated experimentally characterized human protein complex data was 
obtained from CORUM [27], to determine the general promiscuity of RBPs in forming 
complexes. Then 5,217 protein complexes were mapped to the RBPs. For SUR RBPs and 
non-SUR RBPs the frequency of membership in CORUM complexes were calculated, as 
well as the mean complex size. This information together with the log-ratios of 
expression levels between healthy and cancer states in the tissues, allowed us to address 
whether SUR RBPs are enriched in protein complexes and/or occur in larger or smaller 
complexes. This analysis also allowed us to test the relation between the extent of an 
RBP’s dysregulation in the context of its membership. 
2.2.5 Determination of prognostic impact of RNA-binding proteins for breast cancer 
A gene’s prognostic impact is the gene’s ability to impact positively or negatively 
patient survival. The prognostic impact for each gene was determined using data from the 
Kaplan–Meier (KM)-Plotter [28], which was determined from microarray experiments 
for over 20,000 genes for 1,800 breast cancer patients. For each gene in the RBP and 
non-RBP groups, they were further categorized as SUR or non-SUR and high or low 
variability in expression. The significance [-log(KM-plotter P)] of the prognostic impacts 
were compared within and between these groups. 
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Based on the network analyses, the genes were ranked in descending order based 
on their mean path lengths to the classification of dysregulated genes (SUR vs non-SUR). 
Path length calculations were determined from a distance matrix generated by the 
network analysis. From the ranked list of genes, five genes were selected with the 
shortest and longest mean path lengths and took a random sample of five genes with 
intermediate mean path lengths. This provided information on the prognostic impact 
associated with increased gene expression. 
2.3 Results and discussion 
2.3.1 RNA-binding proteins show significantly higher expression than non-RNA-binding 
proteins and other regulatory factors for 16 human tissues 
In eukaryotes, transcription and translation occur in different compartments. This 
gives a plethora of options for controlling RNA at the post-transcriptional level, including 
splicing, polyadenylation, transport, mRNA stability, localization and translational 
control [1,2]. Although some early studies revealed the involvement of RBPs in the 
transport of mRNA from the nucleus to the translation site, increasing evidence now 
suggests that RBPs regulate almost all of these post-transcriptional steps [1–3,29]. RBPs 
have a central role in controlling gene expression at the post-transcriptional level. 
Alterations in expression and mutations in either RBPs or their RNA targets (the 
transcripts that physically associate with the RBP) have been reported to be the cause of 
several human diseases, such as muscular atrophies, neurological disorders and cancer 
[4,5,7,30].  
Therefore, I first chose to study the mRNA expression levels of a repertoire of 
approximately 850 experimentally determined RBPs for all 16 human tissues for which 
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expression data are available from the Human BodyMap 2.0 Project [18,21](see 
Materials and methods). This analysis clearly showed that RBPs are significantly more 
highly expressed (P < 2 × 10-16, Wilcoxon test) than non-RBPs in all of the tissues 
(Figure 5). Closer inspection of the trends also revealed that some tissues, such as those 
from the testes, lymph and ovary, had particularly high RBP expression compared to non-
RBPs. To determine the regulatory effect of RBPs at the post-transcriptional level 
compared to other regulatory factors, such as transcription factors (TFs), microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs), their expression levels were compared 
for different human tissues (see Figure 4 and Materials and Methods).  
This analysis further revealed that the expression levels of RBPs are significantly 
different for these 16 tissues compared to these families of regulatory factors (P < 2 × 10-
16, Kruskal–Wallis test). Further analysis to compare the expression levels of RBPs and 
TFs across tissues revealed that except for the heart, kidney, ovary and testis, RBPs are 
significantly more highly expressed than TFs (P < 0.05, Wilcoxon test). These 
observations suggest that in most tissues, the magnitude of expression of RBPs is more 
prominent than even TFs, possibly indicating their central role in controlling gene 
expression than previously anticipated. The observation that RBPs are not significantly 
more highly expressed than TFs in heart, kidney and gonadal tissues like the testis and 
ovary suggests that both transcriptional and post-transcriptional regulators are equally 
important in terms of their expression levels in these tissues. In contrast, tissues like the 
liver (P < 3.57 × 10-11, Wilcoxon test) and white blood cells (P < 3.85 × 10-5, Wilcoxon 
test) were found to have significantly higher expression for RBPs compared to TFs, 
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possibly indicating the importance of post-transcriptional regulation in the regenerative 




Figure 4: Expression levels of RNA-binding proteins (RBPs), non-RBPs, lncRNAs, 
miRNAs and transcription factors (TFs) for 16 human tissues. Each of the 16 plots 
illustrates the significant differences in expression levels of RBPs (P < 2 × 10-16, Wilcox 
test) for adipose, adrenal, brain, breast, colon, heart, kidney, liver, lung, lymph node, 
ovary, prostate, skeletal muscle, testes, thyroid and white blood cell tissues, compared to 
the other regulatory factors. The x-axis is the category of the observed factor and the y-





Figure 5: Comparison of expression levels of RNA-binding proteins and non-RNA-
binding proteins for 16 tissues from 80 healthy individuals studied in the Human 
BodyMap project. Each of the 16 plots illustrates the significant differences in 
expression levels in RBPs (P < 2 × 10-16, Wilcoxon test) across adipose, adrenal, brain, 
breast, colon, heart, kidney, liver, lung, lymph node, ovary, prostate, skeletal muscle, 
testes, thyroid, and white blood cell tissues. The x-axis is the category of the observed 





The fact that RBPs exhibit a particularly high level of expression in some tissues 
suggests a need for extensive post-transcriptional control of gene expression in them. For 
example, the coordinated and cyclic processes of spermatogenesis in testes necessitate the 
essential temporal and spatial expression of pertinent genes [31]. In the human prostate, 
slight alterations to the androgen receptor functionality [32] or transcription factors [33] 
have been shown to lead to a cancerous state. These trends suggest that a significant 
fraction of the RBPome might play an important regulatory role in diverse human tissues, 
although in some gonadal and developed tissues, RBPs and TFs had similar levels of 
expression. My results show that the high expression of RBPs is especially important in 
developmentally important tissues suggesting that any patterns of dysregulation could 
strongly effect these tissues [8]. 
2.3.2 RNA-binding proteins are dysregulated across cancers and a subset are strongly 
upregulated across a majority of cancers 
 Based on the understanding of the expression landscape of RBPs in healthy 
human tissues, I next asked whether RBPs are dysregulated across cancers (see Materials 
and methods). Since expression data for healthy tissue was available for eight tissues 
from the Human BodyMap project corresponding to a set of nine different cancers 
profiled in the Cancer Genome Atlas (TCGA), I calculated the log-ratio of expression 
levels of RBPs in the healthy to cancerous states in each of the nine cancers (Materials 
and methods). Positive values represent a shift towards upregulation, or, more generally, 
increased transcript abundance. Negative log-ratios represent a trend of downregulation 
or decreased abundance. The log-ratio expression profile matrix for the nine cancers was 
hierarchically clustered to show patterns of similar dysregulation (Figure 6). Cancers in 
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similar tissues (lung adenocarcinoma and lung squamous carcinoma) are clustered 
together suggesting a similar degree of dysregulation of the RBP repertoire. The analysis 
also revealed that similar cancers, such as adenocarcinomas were clustered together. 
These trends indicate that expression ratios are reliable for profiling cancers with unique 
morphologies in various body locations. 
 
Figure 6: Correlation matrix of overall log-ratio expression of RBPs across nine 
cancers. The matrix shows the clustering of similar tissue sites and similar cancer types. 
 An analysis of the log-ratios representing the fold changes in expression of RBPs 
between healthy and cancerous states for nine different cancers allowed us to define a 
criterion for classifying RBPs as strongly upregulated (SUR) or not (non-SUR) (Figure 7, 





























log-ratio for expression level change of at least nine, it was classified as highly 
dysregulated, otherwise it was not considered to be a significantly dysregulated RBP. 
This also corresponded to the RBPs that belonged to the upper quartile of the fold 
changes in expression across cancers. According to this criterion, all the RBPs that had at 
least a ninefold change in expression were found to be only upregulated and hence this 
group was termed SUR RBPs (Figure 7). Table 1 lists these 31 SUR RBPs. 
 I then asked whether tumor-matched normal expression data for TCGA samples 
can further support the set of SUR RBPs identified here. Although ‘normal’ site tissue 
samples from TCGA cannot provide an adequate control, since these samples are 
collected from a cancerous tissue and it is entirely feasible that the expression levels 
would still be in a state of dysregulation at the neighboring sites, this analysis can still 
provide an additional level of support for SUR RBPs. Additionally, it is not possible to 
control for morphological types of tumors, which, depending on their type, can affect 
more than just the site of the tumor growth. Nevertheless, I profiled the tumor-matched 
normal expression levels that are available for eight of the nine cancer types with varying 
number of samples for breast (106 patients), colon (20 patients), kidney (69 patients), 
liver (49 patients), two types of lung cancers (57 and 50 patients), prostate (45 patients) 
and thyroid (58 patients). As suspected, the fold changes in expression for all the genes 
across eight cancers were minimal (median [IQR] 0.055 [-0.28:-0.39]), suggesting that 
tumor-matched normal expression data may not reflect a true healthy control. However, 
when compared to the fold changes in expression levels for RBPs and non-RBPs in the 
tumor-matched samples across cancers, RBPs exhibited significantly higher fold changes 
compared to non-RBPs (median [IQR] 0.104 [-0.07:0.29] for RBPs versus median [IQR] 
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-0.034 [-0.39:0.25] for non-RBPs, P < 2.2 × 10-16, Wilcoxon test) clearly indicating that 
RBPs are still significantly upregulated in tumors.  
 Further analysis to test for the enrichment of RBPs in the top quartile of 
upregulated genes across cancers revealed that RBPs are strongly over-represented in this 
list (P = 1.62 × 10-93, hypergeometric test). I also found that all the SUR RBPs are 
significantly dysregulated (P < 0.001, t-test comparing tumor and matched normal 
samples) in at least four of the eight cancers profiled. When strigency was raised to 
identify an RBP to be dysregulated in at least six or more cancer types, 24 of the original 
31 SUR RBPs were detected at P < 0.001. Very few SUR RBPs from the cancer types 
KIRC and LIHC were found to be significantly altered in the tumor-matched analysis. 
While most of the SUR RBPs were found to be upregulated in the tumor-matched 
analysis, I also found cases of downregulation. Nevertheless, SUR RBPs as a group were 
also found to be strongly over-represented in the top quartile of the upregulated set in the 
tumor-matched analysis (P = 2.16 × 10-8, hypergeometric test), further supporting the 
notion that SUR RBPs identified using an external healthy control across a broad range of 






Figure 7: Log-ratio of expression for cancer to healthy expression for RNA-binding 
proteins in nine human cancers. The x-axis is an index of all the RNA-binding proteins 
that could be extracted from the expression data in the Cancer Genome Atlas. The y-axis 
is the ratio of the median expression level for each gene across patients versus the 
observed expression in the Human BodyMap data. Marked are the 31 strongly 
upregulated RBPs that have an expression ratio over nine across more than half of the 







CCDC124 Coiled-coil domain containing 124 
 
CSTF2 Cleavage stimulation factor, 3′ pre-RNA, subunit 2, 64 kDa [34] 
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked [35–37] 
DKC1 Dyskeratosis congenita 1, dyskerin [38–40] 
EIF1AX Eukaryotic translation initiation factor 1A, X-linked 
 
FAM120C Family with sequence similarity 120C 
 
FLNA Filamin A, alpha [41–44] 
FMR1 Fragile X mental retardation 1 
 
GNL3L Guanine nucleotide binding protein-like 3 (nucleolar)-like [45,46] 
GSPT2 G1 to S phase transition 2 
 
HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 (H') 
 
HTATSF1 HIV-1 Tat specific factor 1 
 
HUWE1 HECT, UBA and WWE domain containing 1, E3 ubiquitin 
protein ligase 
[47] 
LAS1L LAS1-like (Saccharomyces cerevisiae) 
 
MBNL3 Muscleblind-like splicing regulator 3 
 
MECP2 Methyl CpG binding protein 2 (Rett syndrome) 
 
MEX3C Mex-3 homolog C (Caenorhabditis elegans) 
 
NKRF NFKB repressing factor [48] 
NONO Non-POU domain containing, octamer-binding [49,50] 
 
28 
PHF6 PHD finger protein 6 [51–53] 
RBM10 RNA-binding motif protein 10 
 
RBM3 RNA-binding motif (RNP1, RRM) protein 3 [54–57] 
RBMX RNA-binding motif protein, X-linked [58] 
RBMX2 RNA-binding motif protein, X-linked 2 
 
RPGR Retinitis pigmentosa GTPase regulator 
 
RPL10 Ribosomal protein L10 
 
RPS4X Ribosomal protein S4, X-linked 
 
SLC25A5 Solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 5 
 
UBA1 Ubiquitin-like modifier activating enzyme 1 [59,60] 
UPF3B UPF3 regulator of nonsense transcripts homolog B (yeast) 
 
UTP14A UTP14, U3 small nucleolar ribonucleoprotein, homolog A 
(yeast) 
 
Table 1: Strongly upregulated RNA-binding proteins identified from nine cancers in 
humans and their cancer relevant references. 
 Non-RBP log-ratios showing the expression changes were also calculated using 
the external healthy data to determine if the proportion of strongly upregulated genes 
(SURs) in RBPs is significantly enriched. The proportions were significantly different (P 
< 0.05, hypergeometric test) with RBPs having a higher proportion of SURs than non-
RBPs. Several of these SUR RBPs were annotated to function in important biological 
processes, such as regulation of gene expression, transcriptional regulation and transport 
of biomolecules, although very few studies have explored their role in the context of 
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post-transcriptional control, suggesting that their functional roles are far more diverse 
than previously understood and appreciated. 
 Of these RBPs classified as SUR RBPs, several have already been implicated in 
complex genetic disorders and cancer or in cellular regulation and proliferation. 
Identified RBPs, such as NONO, are involved in RNA biogenesis and DNA double-
strand break repair, and have been found to be regulated by other factors, when 
dysregulated potentially promote carcinogenesis [49]. DDX3X, a member of the DEAD 
box RNA helicase family, has been shown to affect Wnt pathways, which leads to the 
developments of cancers [35]. DDX3X has also been demonstrated to promote growth 
and neoplastic transformation of breast epithelial cells [36]. Another SUR RBP, LAS1L 
was identified to interact with PELP1, which is implicated in pancreatic cancers [61]. 
HUWE1 is a member of the HECT family of E3 ubiquitin ligases, which has been 
identified as being overexpressed in breast, lung and colorectal cancers [62]. Indeed, 
increasing evidence now points to the role of novel ubiquitin-protein ligases in binding to 
RNA [63,64]. For instance, ubiquitin-like fold has been recently shown to be 
independently enriched in novel unconventional RBPs identified in the yeast genome 
[65]. The RNA-binding protein RBM3 is associated with cisplatin sensitivity, the 
probability of a patient becoming resistant to cisplatin treatment and a positive prognosis 
in epithelial ovarian cancer [54]. RBM3 has seldom been found expressed in normal 
tissues, but it is more expressed in common cancers, particularly for the nuclear 
expression of Estrogen-Receptor (ER) positive tumors. These findings suggest the 
possible utility of the gene as a positive prognostic marker [55,56]. 
 
30 
 PHF6 encodes a plant homeodomain (PHD) factor containing four nuclear 
localization signals and two imperfect PHD zinc-finger domains and it has been proposed 
that it has a role in controlling gene expression [66]. Inactivating mutations in PHF6 
cause Börjeson-Forssman-Lehmann syndrome, a relatively uncommon type of X-linked 
familial syndromic mental retardation [66–68] . Recent studies show that mutations of 
this gene are implicated in the development of T-cell acute lymphoblastic leukemia and 
mutations have been detected in other forms of leukemia as well, suggesting a strong role 
in tumorigenesis [51,52]. For other nucleolar proteins such as dyskerin (DKC1), which is 
responsible for the biogenesis of ribonucleoproteins and telomerase stability, the loss or 
gain of functions is associated with tumorigenesis [38–40]. Filamin A (FLNA) is an 
actin-binding protein, which interacts with a number of proteins including signaling 
molecules and membrane receptors, and its expression has been correlated with 
metastases in prostate and lung cancers [41,42]. A recent study demonstrated the role of 
FLNA as a nucleolar protein that associates with the RNA polymerase I (Pol I) 
transcription machinery to suppress rRNA gene transcription [69]. Although further 
confirmation of how the global RNA-binding role of unconventional RBPs, like the E3 
ubiquitin ligase HUWE1, contribute to cancer is needed, increasing evidence suggests 
that several enzymes and kinases bind to RNAs to control numerous cellular processes 
[57,63] [65,70]. Recent genome-wide screens for novel RBPs further support these 
observations, suggesting that unconventional RBPs are enriched for enzymatic functions 
[65,71]. Functional enrichment analysis of SUR RBPs using the DAVID functional 
annotation system [72] revealed that RNA splicing, nucleotide binding and ribosome 
biogenesis were the common biological processes associated with these proteins, with a 
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significant fraction of them associated with nucleolus and nuclear lumen cellular 
components. 
 My observations combined with the existing corpus of literature in support of the 
roles for several of these SUR RBPs in cancerous states, suggest that their dysregulation 
could be the cause or result of the cancer phenotypes, especially given that even slight 
alterations in the expression levels of RBPs can bring about large-scale changes in the 
RBP–RNA interaction networks that they control [8]. It is important to note that although 
some of these SUR genes shown in Table 1 have been described in relation to cancer, 
there is little evidence in support of their contribution to either being RBPs or their post-
transcriptional network as a contributing factor for the cancer phenotype. The results in 
this study implicate them as a strongly upregulated set of RBPs across multiple cancers. 
My analysis also corroborates that these significantly dysregulated RBPs are not an 
artifact of aberrations in calculations, or due to variability in patient expression data 
mainly because: (1) most of the patient sample sets are at least of the order of 100 for the 
cancers studied and (2) fold changes in expression levels between healthy and cancerous 
states for each patient were used to calculate the median fold change in expression of an 
RBP to account for extreme outliers. The results also emphasize that these high 
expression levels may be indicative of a major dysfunction of these RBPs in addition to 
dysregulation. For example, the mutated form of PHF6, which is implicated in various 
forms of leukemia, has higher expression. Alternatively, the change in expression may be 
a result of an upstream alteration in the regulatory mechanisms, for example NONO; 
another example is that NKRF expression is regulated by miR-301a [48]. The high 
expression of some of these RBPs may be the result of their normal physiological levels 
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being too low compared to a cancer context, as is the case for the proposed positive 
prognostic marker, RBM3. So, a natural question to ask is whether RBPs have some 





Figure 8: Comparison of normalized network metrics (closeness, betweenness and 
degree) between strongly upregulated (SUR) and non-strongly upregulated (non-
SUR) RNA-binding proteins. The median values for each property are the same and 
there are no significant differences (P > 0.05, Wilcox test). 
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2.3.3 Strongly upregulated and non-strongly upregulated RNA-binding proteins 
exhibit significantly different within-group path lengths and variability in expression is 
related to the number of interactions 
 To identify further characteristics that differentiate SUR RBPs in cancer, I 
calculated the network properties of all the RBPs using a network constructed from the 
experimentally reported set of protein–protein interactions in the human genome obtained 
from the BioGRID database [25] (see Materials and methods). In particular, the shortest 
paths between pairs of proteins were computed within SUR and non-SUR RBP groups 
(that is, distances from SUR RBPs to SUR RBPs and distances from non-SUR RBPs to 
non-SUR RBPs) (Figure 9A). SUR RBPs were found to have significantly shorter path 
lengths to each other when compared to non-SUR RBP path lengths (P < 2 × 10-16, 
Wilcoxon test). Other network metrics such as normalized degree distribution, 
normalized closeness, normalized betweenness and mean path lengths for RBPs in each 
group were also calculated (see Materials and methods). However, there was no 
significant difference between SUR and non-SUR RBPs for these properties (Figure 8). 
This suggests that the interaction properties of an individual RBP (whether it is a hub and 
so on) do not relate to its dysregulation but rather the set of SUR RBPs are closely 
intertwined in the physical interaction network compared to the non-SUR RBPs. 
Although my observations on dysregulation are at the RNA level, it is possible to 
speculate, from the shorter path lengths observed, that the interaction network and 
crosstalk between SUR RBPs could also be perturbed in cancer genomes, with one or 




Figure 9: Interaction profiles of RBPs. (A) Distribution of shortest path lengths 
between every pair of RBPs belonging to SUR and non-SUR RBP groups using the 
protein–protein interactions documented in the BioGRID database [66], shown as violin 
plots. The width of each plot is the frequency distribution and the diamond is the median 
value for the category. SUR RBPs were found to have significantly shorter path lengths 
amongst themselves in comparison to non-SUR RBPs (P < 2 × 10-16, Wilcoxon test). (B) 
Box plot showing the number of interactions identified in BioGRID data for RBPs 
classified by variability levels defined by observed percentiles. The higher the variability 
for a RBP, the higher the observed number of protein interactions (P = 9.247 × 10-16, low 
vs medium; P < 2.226 × 10-16, low vs high; P = 6.6556 × 10-16, medium vs high, KS test). 
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 Since the analysis of the shortest path lengths between RBPs from SUR and non-
SUR groups suggested that the particular protein interaction partners of RBPs might play 
an important role in mediating or cascading the effect of dysregulation, I rationalized that 
the protein complex size and a RBP’s occurrence frequency in protein complexes would 
be related to their sensitivity to dysregulation. RBPs long have been known to form 
protein complexes, and if a key component within a complex is dysregulated or 
malformed, it would affect its overall functionality. If a SUR RBP was very prolific one 
would expect that many patterns of dysregulation would occur downstream as a result of 
the formation of a faulty complex. Furthermore, if these SUR RBPs participate in smaller 
complexes, it may be that their dysfunction will not be regulated or counteracted by other 
members within the complex. From the CORUM data [27] (see Materials and methods), 
five SUR RBPs were identified and 172 non-SUR RBPs were identified. I found that for 
the two classifications of RBPs (SUR vs non-SUR), there were no significant differences 
in distributions for either complex size or complex frequency nor was there any 
correlation with expression levels. While the current coverage of the experimentally 
characterized human protein complexes is very limited, these results indicate that SUR 
and non-SUR RBPs do not have significant differences in terms of their protein complex 
membership. 
 I next asked whether the variability in expression levels of an RBP across cancer 
patients is different between SUR and non-SUR RBPs. To address this question, breast 
cancer was chosen as the disease model due to the fact that it is the cancer with the most 
patient samples in TCGA and would naturally be the most robust dataset for identifying 
variation in the fold changes in expression levels of a RBP.  SUR and non-SUR RBPs did 
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not exhibit significantly different expression variation (P = 0.1212, KS test), which was 
measured as the median absolute deviation (MAD) in the expression fold changes 
between healthy and cancerous tissue across all the patients (see Materials and methods). 
However, an analysis to test the relation between expression variation and the number of 
protein interactions of an RBP revealed that the higher the expression variation, the 
higher the number of protein interaction partners of the RBP (Figure 9B). Indeed, a 
significant difference was noticed in the number of interactions in the classified levels of 
variability for RBPs (P = 9.247 × 10-16, low vs medium; P < 2.226 × 10-16, low vs high; P 
= 6.6556 × 10-16, medium vs high, KS test). In contrast, TFs did not exhibit such 
significant differences in the number of interactions with the classified levels of 
variability (P = 0.8931, low vs medium; P = 0.0014, low vs high; P = 0.01, medium vs 
high, KS test). However, for non-RBPs a significant difference was found between 
medium and high as well as between high and low levels of variability (P = 0.7519, low 
vs medium; P < 2.2 × 10-16, low vs high; P < 2.2 × 10-16, medium vs high, KS test). The 
observation that the higher the variability in expression of a RBP the more interactions it 
has, suggests that fluctuating RBPs whose expression is not tightly controlled might have 
more promiscuous (non-specific) protein interactions (and protein complexes) thereby 
leading to RNA off-targets at post-transcriptional level. My results also suggest that such 
dysregulation may be suppressed or is minimal due to the lower number of interactions 
for RBPs with less variability in expression. The analysis here has focused on the RNA 
expression levels of RBPs though it is likely that there will be influences from diverse 
post-transcriptional regulatory phenomena like alternative splicing, translation control 
and post-translational modifications, which will affect the ultimate protein levels. My 
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observations do provide evidence that RBPs with high variability in expression have a 
higher number of protein interactions. 
2.3.4 Survival contributions of RNA-binding proteins in breast cancer is related to 
network proximity to strongly upregulated RBPs and variability in expression across 
patients 
 Based on the observation that SUR and non-SUR RBPs significantly differ in 
their within-group shortest path lengths, I questioned whether the path length of an RBP 
within the protein–protein interaction network might contribute to its prognostic impact 
for a cancer. Each RBP was ranked in each classification based on the mean path lengths 
to all connected nodes in the BioGRID protein interaction network and also computed the 
mean shortest paths to other nodes belonging to SUR RBPs and non-SUR RBPs. This 
allowed the construction of profiles for overall mean path lengths, lengths within-group 
for members of the SUR and non-SUR groups, and between the groups. The top five 
genes with the shortest and longest mean path lengths, and a randomly selected set of 
genes with intermediate mean path lengths, were selected for the survival analyses 
(Figure 10) (see Materials and methods).  As the mean path lengths between SUR RBPs 
increased, their contribution to prognostic impact increased. This suggests that SUR 
RBPs with longer path lengths, that is, those with higher network distances with respect 
to other SUR RBPs, are more likely to contribute independently to survival as they might 
influence a larger fraction of the dysregulated network of SUR RBPs. On the other hand, 
when non-SUR RBPs were sorted by rank based on their mean path lengths with respect 
to SUR RBPs, I found the opposite trend. This suggests that non-SUR RBPs with shorter 
distances to SUR RBPs contribute to the perturbation of an important section of the RBP 
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protein interaction network. In particular, if a non-SUR RBP has a shorter path length, it 
has a good prognostic impact on survival for patients with breast cancer due to its lower 
expression. SUR RBPs are potentially in a malfunctioning state, and the closer a RBP is 
to them, the more the prognostic impact influenced by the SUR RBP interactions. 
 
Figure 10: Survival of patients with breast cancer for different expression levels and 
path lengths for within and between expression groups of RNA-binding proteins. 
SUR (left) and non-SUR (right) survival for a sample of five RBPs classified by path 
length (shortest, median or longest). Curves in red are survival plots for patients with 
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enhanced expression of the selected genes based on more than 1,800 patients’ expression 
profiles from the KM plot [28]. The within-group path ranking for SUR RBPs suggests 
that as the mean path lengths increase the contribution of the SUR RBPs in prognosis 
tends to increase. While between groups, RBPs having shorter path lengths to a SUR 
RPB contribute the most to prognosis. 
 I then compared the overall significance of the Kaplan–Meier P values (-log[P]) 
for groups of RBPs classified by their level of dysregulation (SUR versus non-SUR) and 
their levels of variability in expression across patients (high, medium and low variability 
determined by quartiles, see Materials and methods) in breast cancer (Figure 6). For both 
RBPs and non-RBPs, there was no significant difference between SUR and non-SUR 
genes in terms of prognosis for survival (P = 0.12 and P = 0.06, KS test) (Figure 11A,B). 
However, when I compared the significance of the P values for survival between SURs 
from RBP and non-RBP groups we found them to be significantly different (P = 0.05, KS 
test). In the comparison between variability levels of genes in RBPs, there was no 
significant difference between the Kaplan–Meier (KM) analysis significance levels (P = 
0.945, low vs medium; P = 0.3566, low vs high; P = 0.1478, medium vs high, KS test) 
(Figure 11C). For non-RBPs, the levels of variability did have a very significant 
difference in the significance of KM-plotter survival P values (P < 2.226 × 10-16, low vs 
medium; P < 2.226 × 10-16, low vs high; P = 6.6556 × 10-16, medium vs high, KS test) 
suggesting that, in general, the higher the expression variation of a group of genes, the 
smaller is their contribution to prognosis for survival (Figure 11D). While there was no 
significant difference in RBPs I did observe a similar weak trend where the lower the 
variance in expression across patients, the greater the KM-plotter significance. A highly 
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variable RBP has less effect on survival because it could potentially be regulated by a 
number of other factors and could be the result of an indirect effect, whereas low 
variability RBPs have a less but more direct effect on the prognosis for an individual and 
hence could be the actual drivers. This also corroborates our notion after observing 
variability versus the number of protein interactions (Figure 7B).   More generally, my 
results suggest that while I observe a larger proportion of SUR RBPs, their elevated 









Figure 11: Comparison and distribution of prognostic impact based on expression 
dysregulation and expression variability in breast tissue. RNA-binding proteins (A, 
C) and non-RNA-binding proteins (B, D) were categorized based on their level of 
dysregulation as healthy or cancer expression (SUR or non-SUR) and the variability of 
expression levels (high, medium or low) in patients with breast cancer. The statistical 
significances for the differences in the distributions of prognostic impact are discussed in 





In this study, I investigated the gene expression profiles of RBPs in healthy 
humans for 16 tissues and found that RBPs are consistently and significantly highly 
expressed compared to other classes of genes (non-RBPs) as well as in comparison to 
well-documented groups of regulatory factors like transcription factors, miRNAs and 
lncRNAs. This, in concordance with previous research, emphasizes their importance in 
post-transcriptional regulatory control across all the tissues. To understand the expression 
profile changes in a disease state for hundreds of RBPs in the human genome, I obtained 
analogous RNA-sequencing-based expression data for a total of 2,876 patient samples 
spanning nine cancers from TCGA and calculated a log-ratio for expression between 
cancer and healthy states. I showed that there is a unique signature of approximately 30 
RBPs that had significantly increased expression levels across six out of nine (two-thirds) 
cancers profiled. These could be clearly labeled as a set of SUR RBPs delineating them 
from the rest of the RBPs based on the change in expression levels. This proportion of 
SUR RBPs in the RBP population is greater than the proportion of SUR non-RBPs 
suggesting for the first time that the expression levels of a significant fraction of the 
RBPs are affected in cancerous states. Analysis of the protein–protein interaction network 
properties for SUR and non-SUR group of RBPs, suggested that the shortest path length 
distributions between SUR RBPs is significantly lower than that observed for non-SUR 
RBPs. This observation together with survival analysis based on path lengths suggests 
that not all the SUR RBPs might be directly implicated in cancer but rather that a cause-
and-effect relation might hold between some of the SUR RBPs.  This observation was 
further supported by the fact that the higher the expression variation of a RBP in breast 
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cancer patients, the higher the number of protein–protein interactions. This indicates that 
fluctuating RBPs whose expression is not tightly controlled (with differing fold changes 
in expression levels across patients) might be involved in more promiscuous (non-
specific) protein interactions thereby leading to variable RNA off-targets at the post-
transcriptional level. 
 To further determine the prognostic impact in breast cancer patients the SUR and 
non-SUR RBPs were ranked based on path length. The two RBP groups had different 
distributions. As the mean path lengths between SUR RBPs increased their contribution 
to prognostic impact increased, suggesting that SUR RBPs with higher network distances 
with respect to other SUR RBPs, are more likely to contribute independently to survival 
as they might influence a larger fraction of the dysregulated network of SUR RBPs. In 
contrast, when a non-SUR RBP had a shorter path to a SUR RBP, there was a significant 
prognostic impact. This suggests that they are closer to the actual contributors of 
pathogenesis at the post-transcriptional level; however, the longer the path lengths, the 
weaker the prognosis. To gain further insight into the contribution of these subsets of 
RBPs in the development of and survival with cancer, I compared the overall significance 
of the Kaplan–Meier P values (-log[P]) for groups of RBPs classified by their level of 
dysregulation (SUR vs non-SUR). This analysis revealed no significant differences 
between groups of SUR and non-SUR RBPs in terms of their prognosis for survival. 
However, generally, the higher the expression variation across patients, the lower the 
prognostic impact of the protein. The results suggest that RBPs from the signature set 
with lower variation in expression levels across patients might be good starting points for 
studying the effect of RBPs in cancer pathogenesis since SUR RBPs with large 
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expression fold changes might be downstream or there might be indirect effects. 
Additionally, common factors that are dysfunctional along the shortest paths in the 
protein interaction networks of SUR RBPs could also provide clues for potential drug 
targets as they can act as regulators for rewiring the post-translational landscape of RBPs 
thereby affecting RNP complex formation. With increasing efforts to uncover the binding 
sites of RBPs in higher eukaryotes using a variety of high-throughput approaches [73,74], 
it should also become possible in the near future to study the differences in the target 
RNA pools between healthy and cancer genomes for several of these SUR RBPs. This 
would provide a global picture of the affected post-transcriptional regulatory networks. 
The global integration of networks governed by post-transcriptional players like miRNAs 
and RBPs together with signaling networks can provide a comprehensive picture of the 
cause of the dysregulation in these RBPs, which can be used to tease apart the 
contributions of local malfunctions and those due to an upstream or downstream effect in 





3. Bottom-up, integrated -omics analysis identifies broadly dosage-sensitive  
genes in breast cancer samples from TCGA 
 
3.1 Background 
 The scientific literature is replete with  papers highlighting the  complex interplay 
between chromosomal instability, aneuploidy, and cancer (e.g. [75] [76] [77] [78]).   
Aneuploidy, the state of having other than the canonical or “euploid” number of 
chromosomes - for humans, 46 - is with only rare exceptions (Downs syndrome, Trisomy 
18) lethal in human embryonic development [79].  By contrast, aneuploidy is observed 
with very high frequency in cancer, leading the eminent German biologist Theodor 
Boveri to speculate as early as 1902 [80] that aneuploidy might have a causative role in 
the disease.   
 Despite previous investigations, there are still important questions.  Is aneuploidy 
a cause or a side-effect of cancer?  If the former, what factors associated with aneuploidy 
contribute to cancer cell fitness?  Are there deleterious impacts of aneuploidy in cancer 
and how are they mitigated during tumorigenesis? More generally, what is the broader 
impact of aneuploidy on gene expression and resulting phenotypes? 
 DNA studies have found that amplification of genomic arms such as 20q and 8q 
[81] [82] occur with high prevalence and have been correlative with cancer severity.  
Understanding how these amplifications impact changes in gene expression and protein 
production is of great interest.  The conventional wisdom regarding gene transcription 
and translation has been that “dosage” generally correlates with product:  DNA to RNA 
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to protein.  Indeed, a recent report finds no evidence for widespread dosage compensation 
in yeast [83].   
 It is customary to use mRNA transcript abundance to identify disease-associated 
genes, but the impact of mRNA abundance on protein production is poorly understood.  
Correlational methods yield weak associations, even when considering protein half-lives 
and other chemical properties [84–87].  Other efforts have been made to integrate  
mRNA dynamics (half-life and fold energy) and RNA Binding Protein (RBP) 
interactions with expression data in S. cerevisiae and S. pombe to aid in predicting protein 
production from gene expression. [88] Illustrates how sequence elements (sequence 
lengths, secondary structures, etc.) were used to identify protein abundance variations.  
Understanding how DNA, RNA, and protein interact is a non-trivial task, but considering 
any of these features in isolation may yield sub-optimal results.  This understanding could 
provide crucial details about tumorigenesis, cancer evolution, and may hold clues to 
potential cancer treatments. 
 In 2015 approximately 40,000 women died of breast cancer in the US alone [89].  
In an effort to better profile and understand cancer, large public efforts have been 
initiated to gather patient data and comprehensively investigate it.  The Cancer Genome 
Atlas (TCGA) collects data for patients across 34 types of cancer profiled using a wide 
array of ‘-omics’ platforms [90].  The unprecedented availability of cancer data, like 






 Here big data methods were applied in a systematic fashion to observe the impact 
of DNA dosage on mRNA transcript levels and subsequent protein concentrations. I 
identify the prevalence of dosage compensation in TCGA breast cancer samples (BRCA), 
highlight dosage-sensitive genes, and investigate the role of these genes in cancer cell 
line survival. 
3.2 Material and methods 
 The data used in this study has been downloaded from multiple resources, 
including TCGA [19], Clinical Proteomic Tumor Analysis Consortium (CPTAC) [91], 
the Catalogue of Somatic Mutations in Cancer (COSMIC) [92], and Achilles short 
hairpin RNA or small hairpin RNA (shRNA) [93]. The data and processing approaches 





Figure 12: Bottom-up, integrated analysis workflow. Visual representation of the 
analytical workflow for identifying broadly dosage-sensitive genes.  Green portions 
represent mRNA-based steps, red protein, blue CNV.  Integrated and filtering steps are 
white.  Briefly, data were acquired from their sources, joined with metadata, normalized, 
integrated, then filtered.   
3.2.1 The Cancer Genome Atlas (TCGA) 
 RNAseq V2 data of 114 normal control patients and 1102 patients with breast 
invasive carcinoma (BRCA) were downloaded from TCGA.   For each of the 20532 
genes of each patient, the median of 114 normal values was used as an estimated 
baseline, which is noted as the Normal median RSEM.  The fold change of each gene, 






     (eq. 1) 
 The corresponding patient metadata was downloaded and mapped based on 
sample IDs extracted from the TCGA barcode. Level 3 TCGA copy number variant 
(CNV) data was extracted for all available patients.  The TCGA CNV pipeline transforms 
a CNV value into a segment mean, where 𝑆𝑒𝑔𝑚𝑒𝑛𝑡	𝑚𝑒𝑎𝑛 = 𝑙𝑜𝑔$(𝐶𝑁𝑉/2). A copy 
number can be derived from the segment means by calculating 2 ∗ (28!04!'9	4!&'). With 
this, the diploid regions will have a segment mean value of zero, amplified regions will 
have positive values, and deletions will have negative values.   
3.2.2 Clinical Proteomic Tumor Analysis Consortium (CPTAC) 
 Mass spectrometry (MS) data for breast invasive carcinoma was downloaded 
from CPTAC; these abundances were reported as the log2-ratio of the expression of the 
sample to a common, healthy pool [94]. Patient mRNA, protein, and CNV data was 
matched using TCGA barcode. Gene identifications for MS data were made using 
previously established methods [95] and were provided by CPTAC.   mRNA, protein, 
and CNV data for a given gene were joined by gene symbol.  The unshared relative 
protein abundance was matched to 106 patients with  mRNA and protein abundance data 
[91].   
3.2.3 Gene amplification and deletion 
 Segment regions were mapped to the UCSC genome coordinates for the hg38 
build of the human genome.  For regions that covered multiple genes, the segment means 
counted for each gene. For genes with multiple calls, the maximum value was kept.   
 For genes across all 106 samples with protein and mRNA data, there were 
1,052,345 segment means in total. The average segment mean was 0.12 ± 0.02.  A gene is 
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defined as amplified if its segment mean is greater than 0.2 and deleted if it is less than -
0.2 [96].  Doing so there are 837,531 normal segments in the patients, 213,361 segments 
are amplified, and 1,453 have deletion events.  Of those, 9835 genes were uniquely 
identified as normal, 9831 as amplified, and 1247 as deleted. Interestingly, only 15 
patients of the 106 had no deletions. 
 To normalize protein and mRNA expression to a similar scale, a z-score 




        (eq.2) 
Where 𝑥∆"#$represents the expression of a given gene, 𝜇∆"#$ the mean expression for the 
data set, and 𝛿∆"#$the standard deviation.   
3.2.4 Cancer gene profiling 
 The Cancer Gene Census was downloaded from COSMIC [92].  Genes labelled 
as amplified were selected and mapped to the results of the integrated genomics analysis 
to annotate correlational signatures.  The Pearson correlation coefficient was calculated 
between protein abundance fold-change, mRNA fold-change, and CNV amplification.  
Any gene with all correlational scores above 0.70 is called a “Broadly Dosage-Sensitive 
Gene,” or BDSG.  The stringent cutoff was selected to emphasize genes as very unique. 
Generally, there was poor correlational concordance among the features (Figure 13).  
This is not to say the genes below this threshold may not be informative, but they are not 




Figure 13: Correlation coefficient cutoff.  Scatter plot of correlation threshold cut offs 
and subsequent member counts. The red, dotted line indicates cutoff used for BDSG 
identification for the study.  
3.2.5 Achilles shRNA 
 Achilles shRNA knockdown data was downloaded and subset for the BDSG 
genes, a selection of housekeeping genes [97] and genes acting as oncosuppressors or 
oncogenes.  shRNA hairpins for each gene were selected based on second-lowest log-
ratio to avoid false positives.  Hierarchical clustering was performed via Python 
clustermap function on the genes, as well as the cell types. Additional hierarchical 
clustering was performed excluding any cell types not related to breast models. 
3.3 Results and discussion 
3.3.1 Genomics and protein analysis 
 RSEM distributions for the 106 breast cancer patients for 20531 genes were 
plotted for both the cancer and healthy samples.  Initial observations of RSEM values 
show similar quantiles suggesting that global expression distributions are similar between 
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tumor-matched normal and tumor samples (Figure 14).  This alleviates concern for the 
impact of any batch-effect or other temporal anomalies in sample processing.   
 
Figure 14: Tumor-matched normal and tumor sample expression distributions.  
mRNA expression distributions for tumor-matched normal and tumor samples. 
Distributions are similar suggesting no batch effect or temporal confounder. This does 
not illustrate changes of a singluar genes expression between the two states, rather 
summary information of expression. 
 Wilcoxon signed-rank test of gene expression between healthy and cancer 
samples detected that over 10,000 genes had significantly different expression (p < 
0.00005).  This emphasizes that the cancer transcriptome varies dramatically from normal 
tissue.  
 The log2 fold-change of mRNA from cancer to healthy was calculated as (eq.1), 
described with a mean mRNA fold change of −9.0 × 10:$ 	± 1.5 (max = 17, min= – 16).  
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This indicates a class of genes that have minimal change and another subset that shows 
large changes in expression as indicated by the distribution (Figure 15). 
 
Figure 15: mRNA log2 fold change from normal median to cancer.  mRNA log2 fold 
change distributions illustrate classes of genes within patients that have high degrees of 
alteration. In this instance we can now identify genes with large log2 fold change 
differences from cancer to healthy states.  
 Fold changes were plotted for protein expression.  For proteins, the mean fold 
change was 3 × 10:$ 	± 0.67 (max = 8.5, min = – 6.5).  Since the dynamic range of 
these effects are not equivalent in both datasets, they were z-score normalized.  After 
normalization, the overall distributions of mRNA and protein fold changes were not 
statistically different (𝑃 = 	0.96, Wilcoxon Test).  Therefore, my normalization practice 
is sufficient to integrate the datasets and attempt to find relationships.  These 
relationships are visualized in Figure 16.  The strikingly poor correlation between the two 
features emphasizes the difficulty in accurately inferring protein levels from given 
mRNA expression values.  A D’Agostino’s K-squared test of the mRNA and protein 
correlations led to the rejection of the null hypothesis that the data was Guassian (𝑃	 <
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	0.0005).  Further examination of QQ plots conveys a trend for a mariginally lighter left 
tail and a heavier right tail to the distribution. 
 
 
Fig 16: mRNA fold change versus protein fold change. This represents the matched 
protein (y-axis) and mRNA (x-axis) z-score normalized, log2 fold changes of disease to 
healthy samples for 106 patients and 20531 genes.  Poor correlation amongst the points 
suggests that mRNA changes do not necessarily predict protein production changes.   
3.3.2 mRNA and protein dysregulation relative to copy number variation 
 There is a strong positive trend for correlation of mRNA fold change with 
segment means. This is intuitive, given if there is an amplification or deletion of a 
genomic region transcriptional activity is impacted.  
 A surprising result is the volume of anti-correlated genes when comparing mRNA 
versus protein fold-changes.  There are 185 genes out of the 9835 with weak, negative 
correlations between mRNA and protein fold-changes.  A negative correlation suggests 
that a regulatory mechanism is either additionally suppressing or enhancing transcript 
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abundance.  There are a number of genes which have negative correlation.  These are of 
relatively low magnitude and lack statistical significance, but there may be underlying 
biological mechanisms at play that may be of interest in future studies.  This notion of 
regulatory interactions is emphasized again by observing the correlation of protein 
changes to segment means (Figure 17).  In this case there are generally weak correlations, 
supporting the concept that precursor genomic features are often not a reliable predictor 
of protein concentration [98].   
 
 
Figure 17: Correlation coefficient distribution.  Overall correlation coefficient 
distributions between genomic features emphasizes the decoupling of mRNA and CNV 
from overall protein production in the TCGA breast cancer samples. 
 Selecting genes and subsequent data based on the 20q chromosomal arm – a locus 
known to be frequently-amplified in breast cancer [99] exemplifies how  DNA 
amplification, mRNA and protein abundance may be discordant. In the case of the gene 
SLPI for a sample (TCGA barcode: D8-A13Y), there is strong DNA amplification, 
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however mRNA and protein abundance is very low.  SLPI encodes an antibody-
producing transcript which antagonizes paclitaxel in ovarian cancer cells [100]. 
 Conversely, there are cases where there is concordance between amplification, 
mRNA abundance, and protein abundance.  In the case of RIMS4, there are very high 
fold changes and amplification in certain members of the cohort.  KM-survivability 
analysis [28] based on microarray data of over 1000 breast cancer patients indicates that 
high RIMS4 expression has a positive prognostic impact (𝑃 < 4.0 × 10:>). 
3.3.3 Cancer gene profiling identifies broadly dosage-sensitive genes (BDSGs) 
 The mRNA, protein, and CNV data for genes labeled as amplified in breast 
cancer from COSMIC is in Figure 18A.   Genes from across the genome that meet the 
Pearson correlation criteria (i.e., all correlations above 0.70) are displayed in Figure 18D 
and listed in Table 2.  Among the genes in Table 2, ERBB2 (HER2, Figure 18C) is a 
member of this group and is a well-known oncogene. In both Figure 18C and Figure 18D, 
there is a strong dosage sensitivity that is atypical across the genome.  The remaining 11 
genes in Figure 18D are not identified in COSMIC at all. GRB7 is a growth factor 
receptor that overlaps with HER2 pathways, and coexpresses with it in esophageal cancer 
[101].  RPS6KB1 is a kinase whose alterations have been associated with an increased 
risk of colorectal cancer [102].  These broadly dosage-sensitive genes (BDSGs) are 
observations on a seemingly rare conservation of the central dogma, yet they have 

























Figure 18: Protein vs mRNA fold changes with CNV amplification.  Figures represent 
the z-score normalized, log2 fold change of mRNA (x-axis) versus protein (y-axis) and 
are colored by CNV segment mean values for samples from patients in the TCGA Breast 
Cancer dataset selected for: (a) Genes in the COSMIC database labelled as amplified, (b) 
known oncogene MYC, (c) known oncogene and BDSG HER2/ERBB2, and (d) all 
BDSGs.  The trend in Figure 18A exemplifies how oncogenecity does not always 
correlate with dosage-sensitivity. 
3.3.4 shRNA data defines the role of BDSGs in cancer cell line growth 
 Figure 19 shows results of testing the impact of BDSGs on cancer cell line growth 
using shRNA.  TUBB is a common housekeeping gene and the signature illustrated in 
19A is typical of this role.  When knocked down by shRNA there is a very deleterious 
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effect on cancer cell line growth and it stands out as a singleton in both heatmaps.  In 
Figure 19A PPME1 and UBE2Z consistently behave as tumor suppressor genes (TSGs) 
across all cell types; their silencing promotes cell viability.  In breast cancer cell lines 
these genes cluster closely with PTEN and RB1 which were included as typical breast 
cancer TSGs.  In contrast, GRB7 and RPS6KB1 have a generally negative impact on cell 
line viability in Figure 19A.  However, when considering just breast cancer-specific cell 
lines, these genes cluster closely and exclusively with ERBB2.  The differences in 
clustering behavior suggest that, unlike PPME1 and UBE2Z, GRB7 and RPS6KB1 act as 
oncogenes very similar to ERBB2.  In fact, GRB7 is co-located with ERBB2 and may be 
upregulated as an adaptation to HER2 (29).  According to the breast-specific cell type 
clustering of shRNA data, BDSGs do not display a subtype-specific role.  They are 




Figure 19: Heatmap and hierarchical clustering of shRNA knockdown.  Section (a) 
represents all cell lines available in the Achilles project and (b) breast-specific cell lines.  
Rows are the selected genes: blue are housekeeping genes, red are oncogenes, green 
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oncosupressors, and light blue are BDSGs; columns are the cell lines.  Red cell values 
represent cellular proliferation, blue cellular death, and white no change.  The clustering 
of ERBB2 and two BDSGs (GRB7, RPS6KB1) in (b) suggests an oncogenic role in 
breast cancer.  PPME1 and UBE2Z signatures in (a) and (b) suggest an overall 
oncosuppressive role. 
3.4 Conclusions 
 In this section I have shown that in the TCGA breast cancer cohort there is 
widespread dosage compensation for the extensive aneuploidy that is observed. The 
dosage of DNA does not generally correlate well with mRNA, nor does the latter 
correlate well with protein levels.  A total of 11 genes show strong correlation across all 
features (DNA/mRNA/protein); analogous to that of a well-known oncogene HER2 
(ERBB2).  These genes are referred to as “Broadly Dosage-Sensitive Genes” or BDSGs. 
It must be noted that they are much less characterized in the literature as to their role, if 
any, in cancer. I advocate further study of BDSGs to better understand their potential 
effects on cancer.  This may lead to new therapies for cancer or biomarkers for improved 
cancer detection. 
 From shRNA data, I show that knockdown of these genes has an impact on cancer 
cell growth. I speculate that tumor cells adapt unusual ploidies to take advantage of 
amplifications and deletions that functionally implicate only subsets of genes.  These 
tumor cells may compensate for the dosage of a large number of “passenger” genes.  This 
may be a vulnerability that could be used for cancer therapy, for example by de-
repressing mRNA and/or protein production from these passenger genes. This may leave 
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the tumor cell with potentially catastrophic levels of unneeded molecules or disrupted 
biological pathways. 
 I also caution that there may be significant pitfalls in drawing conclusions from a 
single type of genomics data.  For example, gene expression (mRNA) data is widely-used 
to infer biological pathway activation, but Figure 16 suggests this would be extremely 






4. Deep Learning and transcriptional signatures for identifying key differentiating 
genes in cancer histologies. 
 
4.1 Background 
 In 2019, the American Cancer Society predicted that in the US alone, 
approximately 23,000 individuals would be diagnosed with ovarian cancer [104], with 
over half that number dying from the disease; and nearly an order of magnitude more 
patients being diagnosed with breast cancer.  By building methodologies to detect  
how these cancer types behave differently at the genetic level, we can better understand 
the pathology of the disease as well as markers to uniquely identify it earlier. 
 The transcriptional landscapes of cancers are a complex series of interactions that 
are difficult to understand.  As stated previously, it is difficult to determine if the changes 
occur as a result of having cancer or they are the driving characteristic of cancer.  With 
developments in genetic engineering and screening, it becomes even more essential to 
understand and detail these subtle differences. 
 The efforts of the Clinical Proteomics Tumor Analysis Consortium allow an even 
more comprehensive view of the samples provided by the TCGA.  Most importantly, the 
investigation can include the transition of genetic components from DNA to protein 
across an additional cancer type.  We can also investigate how these multi-omic 
signatures can identify differentiating and identifying features. 
 The pervasiveness of deep learning methods and frameworks offer the 
opportunity to perform these explorations.  Deep learning is being used extensively in the 
clinical diagnostic space [105–107].  These approaches provide the ability to analyze the 
complex relationship of features in dense datasets such as slide microscopy, medical 
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health records, time series data, or even sequencing data.  Deep learning aids in the 
analysis of complex, multi-modal data. The available frameworks facilitate reproducible 
and transferrable results.  Traditional machine learning and clustering methods struggle 
with correlative datasets, or those with large input parameters.  Deep learning is more 
tolerant of these attributes and can afford quicker paths of analysis.  It allows models that 
are composed of multiple processing layers to learn representations of data with many 
levels of abstraction [108].  Of interest to us is the ability to include the copy number, 
mRNA, and protein changes that occur from a normal to a disease state.   
 I propose examining the multiple facets of genomic data in breast 
adenocarcinoma and ovarian cancer to better understand the transcriptional activity in the 
disease states.  I will compare genes whose gene expressions across multiple features 
(CNV, mRNA, protein) highly correlate in both subsets to determine if there are uniquely 
identifying signatures.  Lastly, I will leverage deep models to classify the samples and 
utilize information and game theory approaches to determine feature importance and 
compare it across gene types. 
4.2 Methods 
4.2.1 Data selection 
 Breast adenocarcinoma mRNA RSEM read counts, copy number variation data, 
and associated metadata for  1097 tumor samples and 121 matched-normal samples from 
The Cancer Genome Atlas [19] were collected along with 375 tumors and six matched-
normal samples from ovarian cancer.  Similar data was collected for ovarian carcinoma 
tumor and matched-normal samples.  From the Clinical Proteomic Tumor Analysis 
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Consortium, iTRAQ uniquely matched spectra were selected for overlapping TCGA 
BRCA and OV samples[94]. 
4.2.2 Data preparation 
 Expression, protein, and copy number variation data were prepared based on 
previous methods [109].  In brief, mRNA RSEM values were calculated as log2 fold 
changes using median, matched-normal sample expression as a healthy state. Copy 
number segment means were changed to copy numbers. mRNA and protein fold changes 
were z-score normalize to center means for further calculations.   
 The Spearman correlation was calculated across all samples between genomic 
datasets: copy number versus mRNA fold changes, mRNA fold changes versus protein 
fold changes, and copy number and protein fold changes.  The higher correlation scores 
across data types will be used to identify broadly dosage sensitive genes (BDSGs) [109] 
and features to be used as input for model generation.  Kolmogorov-Smirnov (KS) 
[110]tests were performed to compare distributions of correlational scores between 
histological data types. 
 Arithmetic means and standard deviations were calculated for the various fold 
changes and scores for exploratory observations.  To assess any differences in expression 
changes Mann-Whitney U tests were performed between BRCA and OV datasets (for all 
genes, BDSGs as a category, and BDSGs per histology).   
4.2.3 Machine learning models 
 A feed forward deep neural network was engineered using the Keras API to 
TensorFlow [111] to classify samples as belonging to one of two histologies: BRCA or 
OV.  The model consists of three input channels, each with four dense layers, 
 
66 
concatenated into inputs to a final series of dense layers to predict the cancer type (Figure 
20).  For each layer besides the output layer, the ReLu activation function was used. 
Since the model is attempting a binary classification (either/or sample classification) the 
sigmoid activation function was used on the final, output layer.  During training the 
ADAM function was used for optimization with a binary cross entropy loss function. 
 The input into the model are the mRNA and protein fold changes as well as the 
DNA copy numbers for 161 samples.  This dataset was split into training and testing sets 
for model training and evaluation.  Input genes were selected to train three models: all 
genes, BDSG, and randomly selected non-BDSG.  For the all gene model, there were 
10,548 genes; 74 for the BDSG-based model; and the random model was selected from 
74 random, non-BDSGs. 
 For comparison to traditional machine learning methodologies a random forest 
model with 1000 estimators was generated using the Python SciKit Learn Random Forest 





Figure 20:  Deep learning architecture for TCGA sample differentiation. Illustrated is 
the multi-input deep neural network (DNN) with a concatenation layer.  Each input channel 
is for the mRNA fold-change, copy number alterations, and protein fold-change. ReLu 
activation functions were used for all but the final layer, which was a sigmoid function.  
Binary cross-entropy was used for the loss function and ADAM as the optimizer. 
4.2.4 Feature selection and importance 
 Shapley additive explanations (SHAP) values were determined using the SHAP 
python package [113] to define input contributions in histological classification in the 
deep models.  This effectively assigns an importance to every input feature for a 
particular prediction on a sample.  The scores aid in investigating which input channels 
(mRNA versus protein versus copy number) seem to drive predictions more regularly, 
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overall which genes seem to be differentiating and potentially important in the cancer 
histology, and if BDSGs fall within those groups. 
 After the SHAP values were calculated in the all features model, hierarchical 
clustering was performed using average linkage and Euclidean distances with the Python 
seaborn package on the fold changes and copy number data to determine if raw values 
could separate histological types.  This was done for each of the input channels to reflect 
initial separation of the samples into their respective classes.  It is important to note this 
methodology provides an estimation, as there are further dense layers after feature 
concatenation. For plotting distributions SHAP values were log-modulus transformed 
[114]. 
4.3 Results and Discussion 
4.3.1 -omics signatures in differing cancer histologies 
 By integrating and joining a variety of genomic features across two cancer 
histologies one is presented with a unique opportunity.  One can examine how patterns in 
expression and alteration influence protein expression and how these patterns can help 
differentiate cancer types.  In BRCA there was a mRNA fold change of -0.0364 ± 0.9389 
(mean and standard deviation), for OV 0.0581±1.004 and that they were significantly 
different (Mann-Whitney U,    𝑃	 < 1 × 10:?@); CNV segment means for BRCA were 
0.0216±0.318, for OV 0.0155±0.411 that that were significantly different (Mann-
Whitney U, 𝑃 < 1 × 10:?@); and protein fold changes in BRCA -0.0003±0.9625, and 
OV 0.0005±0.6711 that were significantly different (Mann-Whitney U, 𝑃 < 3 × 10:AB).  
This high-level comparison supports the intuition that there are unique and differentiating 
transcriptional and translational behaviors in these histologies.   
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 Figure 21 illustrates the correlational relationships between the breast cancer and 
ovarian cancer features.  Each correlational distribution (e.g. mRNA vs Protein scores) 
were found to be significantly different between the two sample classes (two-sample KS, 
mRNA vs protein 𝑃 < 1.0 × 10:?@; mRNA vs CNV 𝑃 < 1.0𝑥10:?@, protein vs CNV 
𝑃 < 1.0 × 10:?@).  From visual inspection of the distributions, the differences in mRNA 
and copy number correlation is striking. In general, it appears that there is better 
correlation between copy number and mRNA changes within ovarian cancer samples. 
Breast cancer also has poorer correlation between mRNA fold changes and protein fold 
changes, suggesting some post transcriptional disruption or activity.  
 
Figure 21:  Correlation distributions for genomic features across BRCA and OV 
genes.  This plot illustrates the correlation distributions between the three genomic 
features for both the BRCA and OV cohorts in this study.  It emphasizes the 
transcriptional differences between BRCA and OV from the mRNA vs Protein and 
mRNA vs copy number differences. 
 I previously determined [109] 16 broadly dosage sensitive genes (BDSG) in 
BRCA.  Using similar criteria 58 genes were identified from the OV cohort 
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(Supplemental Table 1).  These counts are a surprising observation:  the concordance of 
transcriptional activity seems more prevalent in OV samples.   
 Reviewing recent literature for the selected genes impact or relevance to cancer 
revealed their involvement in miRNA regulation or potential prognostic markers.  miR-
142-3p targets PPFIA1 and is implicated in HPV-induced tumorigenesis [115].  MIEN1 
is a migration and invasion enhancer directly targeted by miR-136; suggesting it acts as a 
tumor suppressor and prognostic indicator in osteosarcoma [116,117].  APEX1 is 
targeted by miR-296-3p in non-small cell lung carcinomas and behaves like a tumor 
suppressor, inhibiting migration of cells [118].  The microRNA miR-193a-3p was found 
to slow the progress of HER2 positive breast cancer and was identified as a potential 
therapy candidate; however GRB7 over-expression seemed to counteract its ability to 
inhibit proliferation, migration, and infiltration of breast cancer cells [119].  
Overexpression of Usp14 homologs in Chinese Hamster Ovary (CHO) cells had impacts 
on cell growth with miR-378-3p depletion [120].  miR-146a’s expression impacted tumor 
growth and invasion through the VEGF/CDC42/PAK1 signaling pathway [121].  In two 
cases there was documentation that other regulatory elements were “sponging” miRNAs 
in the environment.  Particularly BFAL1, a lncRNA, was downregulating miR-155-5p 
and miR-200a-3p and regulated RHEB expression.  CBL.11, a circular RNA (circRNA) 
was regulating miR-6778-5p and effected YWHAE expression.  
 PPFIA1 overexpression levels in head and neck squamous cell carcinoma 
(HNSCC) and oropharyngeal squamous cell carcinoma (OPSCC) had associations with 
poor survival [122,123].  Increased metastatic relapse risk in estrogen receptor positive, 
nodal negative (ER+/N-) breast cancer could be indicated by PPFIA1 expression, which 
 
71 
was evidenced via KM analysis [124].  MIEN1 had evidence that positive protein 
production was indicative of a poorer survival rate [125].  Its copy number alterations and 
co-amplification with ERBB2 also highlighted it as a candidate cancer promoting gene 
with shorter overall survival [126].  USP32 was overexpressed in small cell lung 
carcinoma (SCLC) tissues and was highly correlated to disease stage and invasion; 
silencing it caused a decrease in cell proliferation and invasion [127].  Tumor 
proliferation and invasion in NSCLC was facilitated by TIMM50 through its 
modifications of the ERK/P90RSK signaling pathway [128].  
 All 74 BDSGs were selected out of both sample sets.  BRCA BDSG mRNA fold 
change was 0.0474±0.964 (mean and standard deviation), OV -0.0757±1.049; BRCA 
copy number mean was 0.051±0.430, OV 0.063±0.500; and BRCA protein fold changes 
with a mean of -0.001±1.03, OV 0.001±0.929.  In all three cases there were statistically 
significant differences between the two sample types when comparing the between the 
classes of genomic data (mRNA, Mann Whitney U, 𝑃 < 2.0 × 10:?$; CNV, Mann 
Whitney U, 𝑃 < 7 × 10:C; protein, Mann Whitney U, 𝑃 = 0.034).  It is interesting to 
note that while statistically significant, the p-value for protein fold changes between the 
groups is orders of magnitude different from the remaining features. 
 Finally, the expression signatures of the separate BDSG classes were examined: 
16 genes in the breast cancer samples and 58 in ovarian.   For mRNA fold-change in 
expression the breast cancer BDSGs had a mean expression of 0.017±1.09 and ovarian 
samples were -0.088±1.102.  The copy number means for BRCA were 0.186±0.647 and 
OV were 0.087±0.512; protein fold changes in BRCA were -0.109±1.09 and OV were -
0.046±0.970.  Of the histology-specific comparisons only mRNA and protein fold 
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changes were significantly different: Mann Whitney U, 𝑃 = 0.0139 and 𝑃 = 1.13𝑥10:>, 
respectively.  Copy numbers were not significant different between the two groups of 
BDSGs.  Figure 22 visualizes the results.  Ultimately, while there are significant 
differences in the BDSG signatures there is not a clear trend suggesting uniform over- or 
underexpression.  BDSGs do not appear to be a class of enhanced or suppressed genes. 
 
 
Figure 22: Expression distribution comparison between OV-, BRCA-, and non-
BDSGs across genomic datatypes.  The comparison of the values of the BDSG 
signatures in the genomics data illustrate differences in overall distributions between OV 
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and BRCA BDSGs.  In cross-comparisons (e.g. OV BDSG from BRCA samples) there 
are differing distributions, but no distinct enhancement or repression. 
 It can be observed that in general the BRCA BDSGs show a more regular trend 
towards increased fold-changes, the exception being BRCA BDSGs in OV samples.  In 
OV samples, the OV BDSGs reflect a more normal distribution in all but the protein fold 
changes.  In BRCA samples, only in mRNA fold changes does one see a tendency 
towards down-regulation.  This highlights the transcription dysregulation more common 
in breast cancers and coincides with observations in correlation signatures.  
4.3.2 Machine learning approaches 
 The deep learning model had over 31,000 trainable parameters.  Both the all 
feature deep learning model and BDSG-only model had 100% accuracy in predicting the 
tumor types of the validation set samples.  Given the input size of the feature space 
versus the number of samples for the all feature model and the low loss and high 
accuracy, it is a safe assumption that the deep learning models are overfitted.  In this 
case, that is satisfactory.  The classification of histological cancer type acts largely as a 
validation metric for the model.  While observing that protein, mRNA, and copy number 
alterations are unique to separate cancer types; there are much more pragmatic diagnosis 
methods.  My interest is understanding which features drive this predictive process.  To 
further determine prediction sensitivity to feature selection, with a focus on dosage-
sensitivity (correlation of genomic features), non-BDSGs were selected at the same 
volume as BDSGs (n=74).  These models could not differentiate samples.  This helps 
suggests that the signal of BDSG genes within the all features model must still contribute 




Figure 23:  Deep learning test set prediction confusion matrix.  Illustrated is the 
accurate prediction of sample types in the three-channel all gene deep neural network. 
 To confirm the utility of leveraging deep learning versus traditional methods; I 
compared predictions with a random forest model.  I found that no matter the inputs 
provided to the random forest model, it would accurately label samples no matter the 
input size and input selection.  The combination of information-content based 
methodologies and noise in the data seems to cause random forests to overfit, quickly.  
The random forest models also do not capture the nuanced interaction of the multiple 
genomic data types, nor can it offer a probabilistic score or regression value for the class 
assignment.  Even when the input classes are shuffled, the Random Forest model has a 
moderately accurate prediction scheme.  What remains is to determine the distribution of 
SHAP values within and between these two models and what classes of genes exist 
therein. 
4.3.3 Feature importance in deep learning. 
 Briefly, SHAP values are a score based on information and game theory that 
provide an importance for a given feature on a prediction for a sample.  By observing and 
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exploring the distributions of these values genes can be identified which aid in 
emphasizing the sample morphology and cancer significance.  The sign of the value 
(positive or negative) indicates the “direction” of influence of the feature.  For example, a 
negative value in our model indicates a shift towards being classified as a breast cancer 
sample; where positive is towards ovarian.  
 In the all features model there was an observed a mean absolute importance of 
2.86 × 10:B ± 3.50 × 10:B	for mRNA features, 1.28 × 10:@ ± 1.94 × 10:@ for copy 
number features, and 9.59 × 10:@^ ± 1.34 × 10:B for protein.  When selecting for 
previously identified BDSGs out of this model I get the following: 2.55 × 10:B ±
3.54^10:B for mRNA, 1.72 × 10:@ ± 1.07 × 10:B for CNV, 1.07 × 10:B ±
1.33 × 10:B for protein.  The BDSG SHAP signatures across data types were 
significantly different from the remaining non-BDSGs (KS test, 𝑃 < 	1 × 10:?@). 
 One can note how mRNA and protein features drive classification in the all 
features model based on the distribution of SHAP values (Figure 24, Supplemental 
Figure 1).  When considering the mRNA SHAP distributions I can determine the 
differentiating nature of BDSGs.  Within the OV samples BRCA BDSGs indicate a 
positive trend of training (towards an OV classification).  This suggests that the 
expression signatures of these genes are unique and identifying and define the samples as 
‘not BRCA.’  The same trend is observed within the BRCA cohort for OV BDSGs.  If I 
had instead observed a positive trend for OV BDSGs in BRCA patients, this would 
indicate they were being incorrectly suggested as having ovarian cancer.  The BDSGs 
were not necessarily the most important features to the model, however they clearly 





 Figure 24:  SHAP value distribution comparison between OV-, BRCA-, and non-
BDSGs across genomic datatypes.  Distributions of SHAP values emphasize their 
differential behavior. OV and BRCA BDSGs consistently identify sample types. 
 Previously I leveraged correlation across the three genetic data types to help do 
within-histology profiling.   Performing such an exercise allows one to prioritize genes 
that may be effected by transcriptional disruption within a disease state.  By leveraging 
the SHAP values from the deep learning model, I can cross-compare the cancers and 
suggest more subtle differences.  By selecting the top 99th percentile of genes across the 
three input types, a set is generated that was used to perform gene set enrichment analysis 
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(GSEA) [129,130].  Doing so emphasizes two sets that are tied to early/late responses to 
estrogen (𝑃 = 8.01	 ×	10:>; 𝑃 = 1.14	 ×	10:D; hypergeometric test), as well as genes 
regulated by the NF-kB in response to TNF (𝑃 = 4.96	 ×	10:E; hypergeometric test), 
and genes involved in p53 pathways and networks (𝑃 = 2.99	 ×	10:@; hypergeometric 
test).  A number of immunological sets were also identified: genes upregulated by 
STAT5 in response to IL2 stimulation (𝑃 = 2.99	 ×	10:@; hypergeometric test), genes 
encoding components of the complement system, or innate immune system (𝑃 =
2.04	 × 10:>; hypergeometric test), and genes upregulated during transplant rejection 
(𝑃 = 2.99	 ×	10:@; hypergeometric test).  This suggests potential differences in immune 
cell responses or cell populations between the two cancer types; these differences may 
help in developing and understanding new immunotherapies [131].  Most importantly, 
these signatures could not have been detected with expression alone.  The importance 
values were weakly correlated with their respective fold-change values (mRNA: 
3.83	 × 10:$; protein: 5.93	 × 10:$; CNV: −2.57	 × 10:?) indicating that SHAP values 
are not purely a surrogate for differential expression.  Performing the same analysis based 
off of fold-change expression emphasized much more general gene sets such as those 
involved with protein secretion (𝑃 = 5.17	 × 10:E; hypergeometric test) or genes 
involved in homeostasis (𝑃 = 6.45	 × 10:C; hypergeometric test). 
 Interestingly enough, deep learning models with randomly selected genes can still 
perform classification.  The architecture of the model makes it sensitive to genes 
exhibiting tissue sensitivity, age differentiation, or other oncology related genes.  This 
will be emphasized due to the low sample numbers for training and testing.  In the case of 
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this study, I was limited to what is available in TCGA so inherent age and tissue-specific 
biases will exist within the dataset.    
4.4 Conclusions 
 The transcriptional landscape of cancers continues to be a complex model.  By 
examining these samples through a multi-genomics lens, we can begin to understand the 
mechanistic differences between these diseases. There continues to exist a unique subset 
of genes, which show matching changes in copy number, mRNA, and protein changes.  
These genes consistently differentiate the sample morphology, but overall are not the 
most important features for the classification.  What remains to be understood are the 
functional implications of these subclasses.   
 Additionally, more data could be added to capture the regulatory changes that 
may occur.  For example, miRNA or methylation data could help capture any alterations 
or interventions that may occur to inhibit expression.  The investigations have also 
focused predominantly on genes with correlative behaviors.  More complex signatures 
may identify other subclasses of genes that may be interesting.  Genes, where copy 
number and mRNA changes correlate and protein poorly coincide, may illustrate 
interesting subjects of post-transcriptional modifications or regulation.  Further 
explorations should be conducted to understand these patterns and their relationship to 







5. Final Conclusions 
 This body of work represents many years of synthesis, exploration, and analysis.  
Through its course, it has been structured to aid in expanding capabilities in data analysis 
and gathering, familiarizing with the oncogenic landscape, and incorporating bleeding 
edge technical implementations.  It began with merely understanding transcriptional 
activity for important regulators and how they change in cancer.  The project progressed 
to deepening the comprehension of transcriptional regulation in a specific cancer type and 
how those patterns identify genes, and finally, how these discrete patterns can emphasize 
critical functional differences between cancer types. 
 The initial work emphasized RBPs importance, given their consistently significant 
difference across a variety of tissues.  They were found to be highly expressed in a 
variety of cancers, with a subset being many folds over-expressed in a majority of the 
cases.  These strongly upregulated RBPs may potentially have interesting oncogenic 
roles, but cursory investigations based on protein interactions and network metrics did 
not readily identify a causative relationship.  This study was initially a challenge because 
of the immaturity of the TCGA dataset at the time.  Samples and cancer types had to be 
excluded because of missing data and at the time insufficient normal controls were 
available to use as a baseline.  Given the time that has progressed since the initial 
investigation, it would be beneficial for others to attempt to expand on it with additional 
experimental and annotation data. 
 The second phase attempted to address how transcriptional changes in expression 
from healthy to disease states are reflected across the three cornerstone datatypes: 
protein, mRNA, and copy number alteration.  The goal was to understand how 
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amplification impacted overall protein production and what the subsequent mRNA levels 
were like in the change from healthy to cancer states.  The clear trend was the 
staggeringly poor correlation across the three features.  Even more interesting was a small 
subset of genes that had a strong correlation.  This small group included the well-
documented oncogene ERBB2/HER2 and otherwise functionally unannotated genes.  By 
comparing the effects of shRNA knockdown of these genes in cancer models, I illustrated 
how some of these relatively unknown genes behave similarly to known oncogenes and 
oncosupressors.   The complexities of this study centered around the management and 
analysis of large volumes of data.  While the final parsed and processed results were 
small, the initial files and their annotations were multiple gigabytes in size and required 
complex joins and pivots to prepare.  If more mass spectra become available for other 
TCGA datasets, it would be beneficial to continue the exercise to build a library of 
correlational patterns and gene signatures. 
 The third and final phase attempts to compare cancer types based on the gene 
analysis in the second phase, and also leverage deep models to identify key genes that 
may explain the mechanism differences in the two cancers.  From my previous work the 
impact of amplification and deletion is regulated to a large degree was identified in breast 
cancer.  The observation was expanded to ovarian cancer, and immediately there was a 
larger proportion of highly correlative genes. It emphasized a fundamental difference in 
transcriptional or post-transcriptional regulation that was going on in the two cancer 
types.  The deep learning model was trained to differentiate samples.  Not necessarily as 
a classification exercise, but to leverage model explainability methods.  These methods 
aided in the identification of the most important features, or genes, that differentiated the 
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samples.  When compared to random forests or other machine learning approaches, this 
solution provided the most reliable classification and explainability.  Even in comparison 
to the prioritization based on differential expression, deep learning prioritized features 
that identified gene sets pertinent to important, disrupted biological processes.   
 The major complication in working with deep learning models is data availability 
and feature/sample balancing.  While there was a large volume of data on a given 
observation, there was not a large and varied sample set.  This, of course, means my 
model and observations are very much tied to TCGA.  In some cases, extra care had to be 
used to verify that the model was not arbitrarily classifying based on genes correlated to 
age or gender.  Of course, like all the other efforts, when more samples are available with 
the necessary data, the model can only be further improved.  Also, this work was done 
just to classify one cancer type or another.  The dataset and approach can be expanded to 
build deep regressors to predict tumor growth, tumor size, or other features derived from 














Chrom. No. Karyotype band Gene description 





ABCF2 7 q36.1 
ATP binding cassette 
subfamily F member 2 
ABCF3 3 q27.1 
ATP binding cassette 
subfamily F member 3 
ACTN4 19 q13.2 actinin alpha 4 
ADSS 1 q44 adenylosuccinate synthase 
AFG3L2 18 p11.21 
AFG3 like matrix AAA 
peptidase subunit 2  
APEX1 14 q11.2 
apurinic/apyrimidinic 
endodeoxyribonuclease 1  
ARFGEF1 8 q13.2 
ADP ribosylation factor 
guanine nucleotide 
exchange factor 1 
ARFIP1 4 q31.3 
ADP ribosylation factor 
interacting protein 1 
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BROX 1 q41 
BRO1 domain and CAAX 
motif containing  
CAP1 1 p34.2 
cyclase associated actin 
cytoskeleton regulatory 
protein 1 
CDC37 19 p13.2 cell division cycle 37 
CHORDC1 11 q14.3 
cysteine and histidine rich 
domain containing 1  
CTPS1 1 p34.2 CTP synthase 1 
DLAT 11 q23.1 
dihydrolipoamide S-
acetyltransferase  
DNM2 19 p13.2 dynamin 2  
ECH1 19 q13.2 enoyl-CoA hydratase 1  
EIF3J 15 q21.1 
eukaryotic translation 
initiation factor 3 subunit J 
FLOT2 17 q11.2 flotillin 2 
GARS 7 p14.3 glycyl-tRNA synthetase 
GET3 19 p13.13 
guided entry of tail-




GLOD4 17 p13.3 
glyoxalase domain 
containing 4 
HARS 5 q31.3 histidyl-tRNA synthetase 
HNRNPUL1 19 q13.2 
heterogeneous nuclear 
ribonucleoprotein U like 1  
IPO5 13 q32.2 importin 5 
KARS 16 q23.1 lysyl-tRNA synthetase 
LRBA 4 q31.3 
LPS responsive beige-like 
anchor protein 
MACF1 1 p34.3 
microtubule actin 
crosslinking factor 1 
MTAP 9 p21.3 
methylthioadenosine 
phosphorylase 
MTDH 8 q22.1 metadherin 
NSFL1C 20 p13 NSFL1 cofactor 
OPA1 3 q29 
OPA1 mitochondrial 
dynamin like GTPase 
PAFAH1B1 17 p13.3 
platelet activating factor 
acetylhydrolase 1b 
regulatory subunit 1 
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PAK1 11 q14.1 
p21 (RAC1) activated kinase 
1 
PAK4 19 q13.2 
p21 (RAC1) activated kinase 
4  
PDCD6IP 3 p22.3 
programmed cell death 6 
interacting protein  
PGLS 19 p13.11 6-phosphogluconolactonase  
PLAA 9 p21.2 
phospholipase A2 activating 
protein 
PLPBP 8 p11.23 
pyridoxal phosphate binding 
protein  
PTK2 8 q24.3 protein tyrosine kinase 2 
PYCR3 8 q24.3 
pyrroline-5-carboxylate 
reductase 3  
RHEB 7 q36.1 
Ras homolog, mTORC1 
binding  
SARS2 19 q13.2 
seryl-tRNA synthetase 2, 
mitochondrial  
SUGT1 13 q14.3 





SUPT5H 19 q13.2 
SPT5 homolog, DSIF 
elongation factor subunit 
TBCB 19 q13.12 tubulin folding cofactor B 
TIMM44 19 p13.2 
translocase of inner 
mitochondrial membrane 
44  
TIMM50 19 q13.2 
translocase of inner 
mitochondrial membrane 
50  
TRIM33 1 p13.2 
tripartite motif containing 
33 
TSFM 12 q14.1 
Ts translation elongation 
factor, mitochondrial 
UBE2L3 22 q11.21 
ubiquitin conjugating 
enzyme E2 L3  
UFL1 6 q16.1 UFM1 specific ligase 1 
USO1 4 q21.1 
USO1 vesicle transport 
factor 
USP14 18 p11.32 
ubiquitin specific peptidase 
14  
VCP 9 p13.3 valosin containing protein  
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VPS26B 11 q25 
VPS26, retromer complex 
component B 




activation protein epsilon 
ZMPSTE24 1 p34.2 zinc metallopeptidase STE24 
 Supplemental Table 1: Ovarian cancer identified BDSGs, their chromosomal 





Supplemental Figure 1: Heat map and hierarchical clustering of SHAP values for all 
gene deep neural network. By clustering SHAP (columns: genes, rows: samples) values 
we can estimate ‘decisions’ by the model across the three input feature sets to pedict 
 
89 
cancer type (red: OV, blue: BRCA): (a) CNV channel, (b) Protein channel, and (c) 
mRNA channel.  The clustering emphasizes the protein and mRNA contributions through 
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